Extensively drug-resistant mycobacterium tuberculosis (Q49350): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed an Item |
||||||||||||||
| (7 intermediate revisions by the same user not shown) | |||||||||||||||
| description / pt-br | description / pt-br | ||||||||||||||
Micobactérias tuberculosas extensivamente resistentes a medicamentos são resistentes a pelo menos quatro dos principais medicamentos anti-TB. As micobactérias XDR-TB são resistentes aos dois medicamentos anti-TB mais poderosos, isoniazida e rifampicina, também conhecida como multirresistência a medicamentos, além da resistência a qualquer uma das fluoroquinolonas (como levofloxacina ou moxifloxacina) e a pelo menos uma das três drogas injetáveis de segunda linha (amicacina, capreomicina ou canamicina). | |||||||||||||||
| description / en | description / en | ||||||||||||||
Extensively drug-resistant tuberculous mycobacteria are resistant to at least four of the core anti-TB drugs. XDR-TB mycobacteria are resistant to the two most powerful anti-TB drugs, isoniazid and rifampicin, also known as multidrug-resistance, in addition to resistance to any of the fluoroquinolones (such as levofloxacin or moxifloxacin) and to at least one of the three injectable second-line drugs (amikacin, capreomycin or kanamycin). | |||||||||||||||
| Property / Canonical URI | |||||||||||||||
| Property / Canonical URI: https://id.who.int/icd/entity/1947911830 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / CURIE | |||||||||||||||
CID11:MG52.02 | |||||||||||||||
| Property / CURIE: CID11:MG52.02 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Canary Token | |||||||||||||||
dki-india-MG52.02 | |||||||||||||||
| Property / Canary Token: dki-india-MG52.02 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Verification Status | |||||||||||||||
Concluído | |||||||||||||||
| Property / Verification Status: Concluído / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Knowledge Architect | |||||||||||||||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Collection date | |||||||||||||||
13 August 2026
| |||||||||||||||
| Property / Collection date: 13 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Linked ICD 10 | |||||||||||||||
| Property / Linked ICD 10: U84.3 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 19:43, 13 August 2026
Extensively drug-resistant tuberculous mycobacteria are resistant to at least four of the core anti-TB drugs. XDR-TB mycobacteria are resistant to the two most powerful anti-TB drugs, isoniazid and rifampicin, also known as multidrug-resistance, in addition to resistance to any of the fluoroquinolones (such as levofloxacin or moxifloxacin) and to at least one of the three injectable second-line drugs (amikacin, capreomycin or kanamycin).
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | MG52.02 |
||
| English | Extensively drug-resistant mycobacterium tuberculosis |
Extensively drug-resistant tuberculous mycobacteria are resistant to at least four of the core anti-TB drugs. XDR-TB mycobacteria are resistant to the two most powerful anti-TB drugs, isoniazid and rifampicin, also known as multidrug-resistance, in addition to resistance to any of the fluoroquinolones (such as levofloxacin or moxifloxacin) and to at least one of the three injectable second-line drugs (amikacin, capreomycin or kanamycin). |
Statements
CID11:MG52.02
0 references
dki-india-MG52.02
0 references
Concluído
0 references
13 August 2026
0 references
